Both HER2 gene amplification and HER2 receptor overexpression are found in approximately 25% of invasive breast cancers and are associated with a more aggressive clinical phenotype.53 The first agent approved for HER2-positive breast cancer was trastuzumab, which is a humanized monoclonal antibody. This evidence concerns the gene ERBB2 and invasive breast carcinoma.